FdaApplication
NDA 022072
Identifiers
- fda_app_no: NDA022072
Properties
| Property | Value |
|---|---|
| applicant_name | BRISTOL MYERS SQUIBB |
| application_type | NDA |
Revenue by product
SPRYCEL
| Period | Revenue |
|---|---|
| Q2 2026 | $88.0M |
| Q1 2026 | $73.0M |
| Q4 2025 | $80.0M |
| Q3 2025 | $119.0M |
| Q2 2025 | $120.0M |
| Q1 2025 | $175.0M |
| Q4 2024 | $198.0M |
| Q3 2024 | $290.0M |
| Q2 2024 | $424.0M |
| Q1 2024 | $374.0M |
| Q4 2023 | $526.0M |
| Q3 2023 | $517.0M |
| Q2 2023 | $458.0M |
| Q1 2023 | $429.0M |
| Q4 2022 | $578.0M |
| Q3 2022 | $560.0M |
| Q2 2022 | $544.0M |
| Q1 2022 | $483.0M |
| Q4 2021 | $555.0M |
| Q3 2021 | $551.0M |
| Q2 2021 | $541.0M |
| Q1 2021 | $470.0M |
| Q4 2020 | $564.0M |
| Q3 2020 | $544.0M |
| Q2 2020 | $511.0M |
| Q1 2020 | $521.0M |
| Q4 2019 | $549.0M |
| Q3 2019 | $558.0M |
| Q2 2019 | $544.0M |
| Q1 2019 | $459.0M |
| Q4 2018 | $536.0M |
| Q3 2018 | $491.0M |
| Q2 2018 | $535.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| SPRYCEL | DASATINIB | 70MG | TABLET;ORAL |
1 product